Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210170

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210170

Trastuzumab Biosimilars Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Trastuzumab Biosimilars Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trastuzumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for trastuzumab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The trastuzumab biosimilars market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product: Ogivri; Herzuma; Ontruzant; Trazimera; Other Products

2) By Indication: Adjuvant Breast Cancer; Metastatic Breast Cancer; Metastatic Gastric Cancer; Other Indications

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy

Companies Mentioned: Amgen Inc.; Pfizer Inc.; Samsung Bioepis; Merck & Co.; Biocon Limited

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the trastuzumab biosimilar market are: Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc.

The global trastuzumab biosimilars market is expected to grow from $2.08 billion in 2021 to $2.64 billion in 2022 at a compound annual growth rate (CAGR) of 27.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The trastuzumab biosimilar market is expected to reach $6.90 billion in 2026 at a CAGR of 27.1%.

The trastuzumab biosimilar market consists of sales of herceptin, avastin, and Kanjinti. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Trastuzumab biosimilar refers to a HER2-targeted therapy drug that are designed to treat early and metastatic HER2-positive breast cancers. Trastuzumab biosimilar is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2)/neu receptor and renders it inactive

North America was the largest region in the trastuzumab biosimilar market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the trastuzumab biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of products in trastuzumab biosimilar are ogivri, herzuma, ontruzant, trazimera, and others. The different indications include adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others and are distributed through hospital pharmacy, and online pharmacy.

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer. According to the World Health Organization (WHO), breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the market.

The side effects of trastuzumab biosimilar are expected to limit the growth of the trastuzumab biosimilar market. The side effects of Herceptin (chemical name: Trastuzumab) include diarrhea, nausea, fever, heart problems, infection, cough, and rashes. Moreover, breast cancer studies reflect that exposure to trastuzumab (Herceptin) therapy increased the rate of asymptomatic cardiac dysfunction in the two-year trastuzumab treatment from 4.6% to 8.1%. The rate of at least one patient experiencing Grade-3 or higher, for treatment with trastuzumab is at 20.4% for two years, compared to 16.1% for one year of treatment. The side effects of trastuzumab hurt the trastuzumab biosimilar market.

Major players are continuously focusing on launching new products in the untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, and geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers. For instance, in February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer. Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab)- ONTRUZANT(trastuzumab-dttb). ONTRUZANT is available in the USA for approximately $1,325 and $3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, acquired Viatris Inc for $3.3 billion. This acquisition would build a distinctive, fully integrated, global biosimilars enterprise. This strategic alliance combines the strengths and complementary skills of both parties, positioning Biocon Biologics for the next ten years of value generation for all of our stakeholders. Viatris Inc is a US-based pharmaceutical company and a developer of biosimilar trastuzumab.

The countries covered in the trastuzumab biosimilar market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The trastuzumab biosimilar market research report is one of a series of new reports from The Business Research Company that provides trastuzumab biosimilar market statistics, including trastuzumab biosimilar industry global market size, regional shares, competitors with a trastuzumab biosimilar market share, detailed trastuzumab biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the trastuzumab biosimilar industry. This trastuzumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2023

Table of Contents

1. Executive Summary

2. Trastuzumab Biosimilars Market Characteristics

3. Trastuzumab Biosimilars Market Trends And Strategies

4. Trastuzumab Biosimilars Market - Macro Economic Scenario

4.1 COVID-19 Impact On Trastuzumab Biosimilars Market

4.2 Ukraine-Russia War Impact On Trastuzumab Biosimilars Market

4.3 Impact Of High Inflation On Trastuzumab Biosimilars Market

5. Trastuzumab Biosimilars Market Size And Growth

  • 5.1. Global Trastuzumab Biosimilars Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Trastuzumab Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Trastuzumab Biosimilars Market Segmentation

  • 6.1. Global Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Ogivri
  • Herzuma
  • Ontruzant
  • Trazimera
  • Other Products
  • 6.2. Global Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Adjuvant Breast Cancer
  • Metastatic Breast Cancer
  • Metastatic Gastric Cancer
  • Other Indications
  • 6.3. Global Trastuzumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy

7. Trastuzumab Biosimilars Market Regional And Country Analysis

  • 7.1. Global Trastuzumab Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Trastuzumab Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Trastuzumab Biosimilars Market

  • 8.1. Asia-Pacific Trastuzumab Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Trastuzumab Biosimilars Market

  • 9.1. China Trastuzumab Biosimilars Market Overview
  • 9.2. China Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Trastuzumab Biosimilars Market

  • 10.1. India Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Trastuzumab Biosimilars Market

  • 11.1. Japan Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Trastuzumab Biosimilars Market

  • 12.1. Australia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Trastuzumab Biosimilars Market

  • 13.1. Indonesia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Trastuzumab Biosimilars Market

  • 14.1. South Korea Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Trastuzumab Biosimilars Market

  • 15.1. Western Europe Trastuzumab Biosimilars Market Overview
  • 15.2. Western Europe Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Trastuzumab Biosimilars Market

  • 16.1. UK Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Trastuzumab Biosimilars Market

  • 17.1. Germany Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Trastuzumab Biosimilars Market

  • 18.1. France Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Trastuzumab Biosimilars Market

  • 19.1. Eastern Europe Trastuzumab Biosimilars Market Overview
  • 19.2. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Trastuzumab Biosimilars Market

  • 20.1. Russia Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Trastuzumab Biosimilars Market

  • 21.1. North America Trastuzumab Biosimilars Market Overview
  • 21.2. North America Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Trastuzumab Biosimilars Market

  • 22.1. USA Trastuzumab Biosimilars Market Overview
  • 22.2. USA Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Trastuzumab Biosimilars Market

  • 23.1. South America Trastuzumab Biosimilars Market Overview
  • 23.2. South America Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Trastuzumab Biosimilars Market

  • 24.1. Brazil Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Trastuzumab Biosimilars Market

  • 25.1. Middle East Trastuzumab Biosimilars Market Overview
  • 25.2. Middle East Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Trastuzumab Biosimilars Market

  • 26.1. Africa Trastuzumab Biosimilars Market Overview
  • 26.2. Africa Trastuzumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa Trastuzumab Biosimilars Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Trastuzumab Biosimilars Market Competitive Landscape And Company Profiles

  • 27.1. Trastuzumab Biosimilars Market Competitive Landscape
  • 27.2. Trastuzumab Biosimilars Market Company Profiles
    • 27.2.1. Amgen Inc.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Pfizer Inc
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Samsung Bioepis
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Merck & Co.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Biocon Limited
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Trastuzumab Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Trastuzumab Biosimilars Market

30. Trastuzumab Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!